Yahoo
    Paris - Delayed Quote EUR

    Innate Pharma S.A. (IPH.PA)

    1.2360 -0.0200 (-1.59%)
    As of 10:03:06 AM GMT+1. Market Open.
    Loading Chart for IPH.PA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Innate Pharma Q4 Earnings Call Highlights

    Innate Pharma Q4 Earnings Call Highlights
    MarketBeat 7mo ago
    Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy

    Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy
    PREMIUM
    MT Newswires 11mo ago
    Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

    Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
    Zacks 11mo ago
    Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...

    Innate Pharma SA (IPHA) Full Year 2025 Earnings Call Highlights: Strategic Advances and ...
    GuruFocus.com 7mo ago
    Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

    Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
    GlobeNewswire 6mo ago
    How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 Target

    How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 Target
    Simply Wall St. 7mo ago
    Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

    Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
    Business Wire 6d ago
    Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

    Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
    Business Wire 12d ago
    Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

    Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
    Business Wire 13d ago
    Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround

    Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
    Zacks 24d ago
    Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

    Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
    Zacks 27d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: